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Colorectal cancer (CRC) is the second leading cause of can-
cer death in the United States. Annually, approximately
130,200individualswillbediagnosedand56,300willdiefrom
this disease.1 In general, CRC evolves in an “adenoma to car-
cinoma” sequence during which a series of somatic alterations
accumulateintheDNAofthetumortissue.Since1987,signif-
icant strides have been made in characterizing the genetic
events that lead to colorectal cancer. This work has been based
on detailed clinical and molecular genetic studies of colorectal
tumors. Acquired genetic alterations seen in tumors include
APC and MCC on chromosome 5q, KRAS on chromosome
12p, DCC on chromosome 18q, GTBP (hMSH6) on chromo-
some 2p, and p53 on chromosome 17p.2 In addition, develop-
mentofthesegeneticalterationsmaybeacceleratedbymolec-
ular instability or chromosomal instability.3–4 About 75% of
the time, molecular alterations are sporadic events, but the
remaininginstancesariseinindividualswithafamilyhistoryof
colon cancer.5
Animportantstrategyinidentifyinggenesinvolvedincolo-
rectal neoplasia has been the study of colorectal cancer syn-
dromes, through which it has been found that specific genes
are the basis of inherited cancer susceptibilities. Mutations in
severalgeneshavebeenassociatedwithhereditarycancer:APC
gene in familial adenomatous polyposis (FAP) and the DNA
‘mismatch repair’ genes, hMSH2, hMLH1, hPMS1, hPMS2,
and hMSH6 (GTBP) in hereditary nonpolyposis colorectal
cancer (HNPCC).6–10 A novel locus has been reported on
chromosome 15q in a multiplex CRC family, and the gene has
beennamedCRAC(colorectaladenomaandcarcinoma).11Al-
though these currently known susceptibility genes account for
, 10% of all colorectal cancers, there remains at least 20% of
patients who have family histories of colon cancer and for
which mutations in genes remain to be identified.5,7
Familial adenomatous polyposis
Germline mutations (primarily nonsense, frameshift) of
APC are associated with FAP, an autosomal dominant syn-
drome, which is clinically characterized by young onset (age
12–15 years), hundreds of adenomatous polyps in the colon,
and increased risk for gastric polyps, duodenal cancer, thyroid
cancer, and desmoid tumors.9 An attenuated variety (AFAP)
has fewer than 100 adenomas with proximal predominance
andlaterageofonset(55years).Ingeneral,AFAPisassociated
with APC mutations that occur near the 39 and 59 ends of the
gene.12–14 Missense mutations in APC have also been reported
in non syndromic colorectal neoplasia families.15,16
A recently discovered missense mutation in APC, known as
APC I1307K, is associated with an increased risk for colorectal
adenomas and carcinoma, but not as high as in FAP.17 This
mutation,whichhasbeenfoundtooccuronlyintheAshkenazi
Jewishpopulation,withaprevalenceof6%,isfoundin10%of
colorectal cancer patients who are of Ashkenazi Jewish heri-
tage, and up to 28% of such patients who also have a positive
family history of colon cancer. This particular mutation does
not in itself cause polyposis or cancer, but instead is a true
cancer predisposition gene, because it creates an instability in
the colon cell’s APC gene (making it hypermutable) that then
maydevelopamoredeleteriousmutationthatcanleadtocan-
cer. This novel mechanism for cancer predisposition may par-
tially explain the reduced penetrance of the mutation. Others
haveconfirmedthisobservation18–20;forexample,Woodageet
al.18 have confirmed the relatively high frequency of this mu-
tation, finding 7.2% of over 5,000 Ashkenazi Jews to be
carriers.
Hereditary non-polyposis colon cancer
Germline mutations in five mismatch repair-related genes
(hMSH2, hMLH1, hMSH6, hPMS1, and hPMS2) cause
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the tumor, characterized by high microsatellite instability
(MSI-H).21,22HNPCCischaracterizedbyyoungonsetcolorec-
tal cancer (mean age 44 years), proximal colon location, mul-
tiple primary cancers, and increased risk of endometrial can-
cer, transitional cell cancer of the ureters, small bowel cancer,
gastric cancer, bile duct cancer, and ovarian cancer.23,24
Microsatellite instability (MSI) in the tumor is associated
withHNPCCandtumorswithspecificpathologiccharacteris-
tics,suggestingagroupofpatientsonwhomsuchanalysismay
be useful.21,22 Recently, in a large retrospective study, MSI has
been found to be associated with improved survival in young
colorectal cancer patients, at all stages, potentially heralding
the use of MSI in treatment decisions or risk management.25
Technology
Germline genetic testing
Gene tests for colorectal cancer (see Table 1) in the clinical
setting primarily consist of the following:
c Protein truncation testing (in vitro synthesized protein
assay) for truncating germline mutations of APC, MSH2,
and MLH1 in patients where the mutation is not known.
This method detects disease-causing mutations (non-
sense or frameshift) that result in premature protein ter-
mination.Inparticular,APCmutationsinthemajorityof
patients with classic FAP phenotype may be detected this
way.26–30 This method is less sensitive for HNPCC, be-
cause other types of mutations contribute to the disease
phenotype.31 If the truncated protein is detected by this
assay in the affected patient, then the defect can be simi-
larly assayed in a focused evaluation of at-risk relatives.
c CSGE, SSCP, or other screening assay, followed by DNA
sequencing for MSH2 and MLH1 in HNPCC families
where the mutation is not known. These methods are
more sensitive than protein truncation testing, but may
still not detect all mutations.31–33 Once a disease-associ-
ated germline mutation is detected in an affected patient,
then ASO methods (described next) can be employed to
evaluate at-risk relatives.
c Allele specific oligonucleotide (ASO) hybridization is ap-
propriate when the specific disease-causing mutation is
known, in cases such as APC I1307K,17 or predictive test-
ing in an FAP or HNPCC kindred where the causal mu-
tation has been identified.31,34
Tumor assays for genetic predisposition
Theavailabilityofarchivalparaffin-preservedcolorectaltis-
sue (normal and tumor) enhances our ability to evaluate pa-
tients or families suspected of harboring HNPCC mutations.
There are two approaches that are moving into clinical
application:
c Microsatellite instability (MSI) is considered to be a fea-
sible and informative option in evaluating a family sus-
pected of HNPCC.21,22,35 Patients with colorectal cancer
Table 1
Genetic tests for susceptibility to colon cancer
Cancer type Test name Method (reference)
Estimated analytic
sensitivity/specificity Sample Indication
HNPCC MSI, IHC Microsatellite instability analysis
(22) and immunohistochemical
staining (38–40)
85%/85% Paraffin block
(tumor)
Affected individuals with colon or
uterine cancer in families with $3
cases of colon or uterine cancer, or
early-onset colon cancer; if tumor
manifests MSI, germline mutation
analysis should be considered
HNPCC MSH2,
MLH1
DNA sequencing (i.e., 31) 70%
a/99% Whole blood (14 mL
lavender top tube)
Affected individuals in families with
greater $3 cases of colon or uterine
cancer; if prior MSI tumor assay
done, probability of germline
mutation is low if tumor was
microsatellite stable
HNPCC MSH2,
MLH1
Protein truncation (28–30) 50%
a/99% Whole blood (7 mL
lavender top tube)
Affected individuals in families with
$3 cases of colon cancer tested first;
unaffected at-risk relatives tested
only if affected patient mutation
detected
FAP APC Protein truncation (26–27) 75%/99% Whole blood (7 mL
lavender top tube)
Affected individuals tested first;
unaffected at-risk relatives tested
only if affected patient mutation
detected
Familial colon
cancer
APC I1307K ASO (17) 99%/99% Whole blood (7 mL
lavender top tube)
Affected and unaffected individuals
of Ashkenazi Jewish ethnicity with
family history of colon cancer
aAt least three other genes account for the other 30% of cases.
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sidered for further germline mutation analysis, particu-
larly if the family history and the value of risk assessment
for family members is warranted.9,36 If the MSI result is
negativeorequivocal,oneshouldstillrelyonthestrength
of the family history to make screening recommenda-
tions,33–37 since up to 15% of colorectal tumors from
HNPCCpatientswillnotdisplaythephenotype.Likewise,
an equal number (15%) of apparently sporadic tumors
are MSI positive.
c Promising new research suggests that immunohisto-
chemistry (IHC) for MLH1 and MSH2 expression is an
inexpensive first screen of CRC tumors to evaluate
whetherMSIand/orgermlinetestingisindicated.Lackof
expression of either MSH2 or MLH1 by IHC in tumors is
correlated with MSI in the tumor.38–40 The majority of
MSI observed in sporadic cases appear to be due to so-
matic hypermethylation of the MLH1 promoter.41,42 It
hasalsobeenobservedthatabsentMSH2IHCexpression
isassociatedwithgermlineMSH2mutation,andaminor-
ity of absent MLH1 IHC expression is associated with
germlineMLH1mutation.42Thetranslationofthesenew
methods into routine clinical practice awaits large-scale
validation studies.
Future technology: conversion of diploidy to haploidy
Recently, Vogelstein and coworkers have developed a new
technique whereby mutations in APC, MSH2, or MLH1 may
be detected by converting diploid cells to haploid cells by se-
lectively fusing with mouse cells and screening the human
chromosome of interest. Also termed monoallelic mutation
analysis, this method may be more widely available in the near
future.32,43
Unresoved issues
There are a number of issues that need to be considered in
the context of colon cancer genetic testing options. The char-
acterization of genetic susceptibility to colon cancer is a very
active area of research, and until studies on large populations
of patients are completed, precision in risk assessment and
screening or preventive interventions will be based on current
best evidence. With respect to FAP and HNPCC, genetic tests
are part of the spectrum of clinical information gathering,
through which management options can be developed. The
clinical, technical, and psychosocial frameworks (both the
medical as well as the patients’ point of view) should be incor-
porated in testing strategies.
1. How many genes are going to turn out to have an effect on
colon cancer, especially the hereditary form?
Forexample,thesyndromeHNPCCisduetoaclassofgenes
thatareinvolvedintheDNAmismatchrepairpathway,sothat
essentially the identical clinical diagnosis can be explained by
any of five different genes. While a majority of mutations are
found in just two genes (MSH2 and MLH1), if no mutation is
foundinthesetwo,therearefewotherclinicaltestingoptions.
Only a few research laboratories are studying mutations in the
other three genes. Yan et al.32 suggest that the majority of
HNPCC families that manifest MSI tumors will be accounted
forbyMSH2andMLH1.Intotal,however,mutationsinthese
genes only account for approximately one half of the families
that fit the Amsterdam criteria (particularly those that do not
manifest MSI); thus, additional genes are likely to be involved
that may have other underlying mechanisms of action.
2. What is the clinical spectrum associated with mutations in
“colon cancer” genes?
Molecular diagnostic testing can better characterize syn-
dromes or even split syndromes that were originally consid-
eredasingleentityonclinicalobservationgrounds.Forexam-
ple,therearemorecancersoftherenalpelvis,ureter,stomach,
and ovaries when the family harbors a mutation in MSH2 (vs.
MLH1), while mutations in MLH1 that completely silence the
gene product (i.e., no protein produced) have a paucity of
extracolonic tumors. An atypical phenotype is seen in families
with MSH6 mutations where endometrial/ovarian cancers
outnumber colorectal cancers. Further differentiation must
awaitlong-termfollow-upofmultiplefamilieswithwell-char-
acterized mutations.
In another example, Turcot syndrome was thought to be an
autosomalrecessiveconditioncharacterizedbycolonicpolyp-
osisandbraintumors.Mutationanalyseshavenowshownthat
Turcot syndrome can be split into at least two dominant pol-
yposis syndromes: (1) the true Turcot syndrome, which is as-
sociated with glioblastoma and is due to mutations at MLH1
and PMS2; and (2) the Crail syndrome, which is associated
with a different brain tumor and medulloblastoma, and is due
to mutations in APC.44
As geneticists study the action of these genes and the muta-
tions in different regions, more subtle phenotypes are being
associated with each [e.g., 15–16]. This finding has the poten-
tial to complicate the management of carriers until such time
thatthemostcompletespectrumofpotentialtumorshasbeen
identified. Individuals shown to harbor pathologic mutations
should remain in an ongoing surveillance program.
3. What is the best surveillance for carriers?
The American Cancer Society, American Gastroenterology
Association,andNationalCancerCenterNetworkhavedevel-
oped recommendations and practice guidelines that consider
genetic risk for surveillance of individuals from familial or he-
reditary colorectal cancer pedigrees.45,46 These recommenda-
tions are largely based on retrospective clinical observations
and expert opinion, as there are no data from large-scale pop-
ulation-based or prospective studies of cancer risk in carriers.
Moleculartestinghasthepotentialtoimprovemanagement
ofmutationcarriers.Forexample,theattenuatedformofFAP
(AFAP),whichischaracterizedbyfeweradenomasandmaybe
of later onset, should be diagnostically followed by colonos-
copy rather than sigmoidoscopy as is standard for classic
FAP.47 HNPCC also requires colonoscopy to monitor for pol-
yps.48 It is the hope, anecdotally observed, that there would be
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Informed consent
The American Society of Clinical Oncology49 has developed
a list of elements of informed consent for cancer genetic test-
ing, including (1) information on the specific test being per-
formed, (2) implications of a positive and negative results, (3)
possibility that the test will not be informative, (4) options for
risk estimation without genetic testing, (5) risk of passing a
mutationtochildren,(6)technicalaccuracyofthetest,(7)fees
involved in testing and counseling, (8) risks of psychologic
distress, (9) risks of insurer or employment discrimination,
(10) confidentiality issues, and (11) options and limitations of
medical surveillance and screening following testing. It is rec-
ommended that all testing be done with a comprehensive in-
formed consent document.
Summary
Colorectalcancergenediscoverieshaveledtoclinicalappli-
cation in the form of improved cancer genetic risk assessment
and genetic testing for hereditary colon cancer, including FAP
and HNPCC. However, much more continues to be learned
about the biology and clinical aspects of colon cancer
susceptibility.
c Germline gene test for FAP utilizes a protein truncation
test of APC.
c GermlinegenetestforAPCI1307KisanASO-basedassay
and may identify persons of Ashkenazi Jewish origin who
are at increased risk for colon neoplasia.
c HNPCC is genetically heterogeneous but is largely due to
mutations in MSH2 and MLH1. Mutations in these mis-
match repair genes often result in microsatellite instabil-
ity (MSI) in the tumor. Tumor assays for MSI may help
identifypersonswhoarelikelytocarrygermlineMSH2or
MLH1 mutations.
c Germline gene tests for MSH2 and MLH1 utilize protein
truncation and DNA sequencing strategies.
c Genetic counseling is an important and crucial compo-
nent of the genetic risk assessment process. Informed
consent for genetic testing is an integral part of the pro-
cess, and a clear understanding by the patient can only be
arrived at by careful counseling.
c In view of the complicated and evolving technology and
clinical issues, individuals with a family history of colon
cancerwouldbebestservedinprogramswithappropriate
laboratory and clinical expertise.
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